{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:56:52Z","timestamp":1761490612849,"version":"3.40.5"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.exphem.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T15:07:56Z","timestamp":1532099276000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-2946","authenticated-orcid":false,"given":"Sara","family":"Ghorashian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Persis","family":"Amrolia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Veys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.07.002_bib0001","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0002","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2005.05572.x","article-title":"Outcome after first relapse in childhood acute lymphoblastic leukaemia: Lessons from the United Kingdom R2 trial","volume":"130","author":"Roy","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0004","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.07.002_bib0005","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short\u2013course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0006","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2010-07-294678","article-title":"Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group","volume":"117","author":"Freyer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0007","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1200\/JCO.2006.07.1225","article-title":"Pathways through relapses and deaths of children with acute lymphoblastic leukemia: Role of allogeneic stem-cell transplantation in Nordic data","volume":"24","author":"Saarinen\u2013Pihkala","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0008","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/bmt.2012.209","article-title":"Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies","volume":"48","author":"Bajwa","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.07.002_bib0009","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bmt.2012.195","article-title":"Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia","volume":"48","author":"Poon","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2018.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2018.07.002_bib0011","doi-asserted-by":"crossref","first-page":"51581","DOI":"10.18632\/oncotarget.9955","article-title":"Immunotherapy of acute leukemia by chimeric antigen receptor\u2013modified lymphocytes using an improved Sleeping Beauty transposon platform","volume":"7","author":"Magnani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2018.07.002_bib0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0013","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1172\/JCI41446","article-title":"Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation","volume":"120","author":"Flutter","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.07.002_bib0014","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.4049\/jimmunol.1401703","article-title":"CD8 T-cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T-cell receptor","volume":"194","author":"Ghorashian","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0015","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2018.07.002_bib0016","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22\u2013specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.exphem.2018.07.002_bib0018","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0020","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.07.002_bib0021","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.07.002_bib0022","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0023","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0024","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0025","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B-cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.07.002_bib0026","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","article-title":"Gene therapy with the Sleeping Beauty transposon system","volume":"33","author":"Kebriaei","year":"2017","journal-title":"Trends Genet"},{"key":"10.1016\/j.exphem.2018.07.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0028","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0029","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.07.002_bib0031","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0032","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2018.07.002_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0034","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2018.07.002_bib0036","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T-cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"10.1016\/j.exphem.2018.07.002_bib0037","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0038","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0039","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V122.21.67.67","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL","volume":"122","author":"Frey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V130.Suppl_1.806.806","article-title":"A novel low affinity CD19CAR results in durable disease remissions and prolonged CAR T-cell persistence without severe CRS or neurotoxicity in patients with paediatric ALL","volume":"130","author":"Ghorashian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0041","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0042","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0043","first-page":"2561","article-title":"CTL019 model-based cellular kinetic analysis of chimeric antigen receptor (CAR) T cells to characterize the impact of tocilizumab on expansion and to identify correlates of cytokine release syndrome severity","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0044","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.exphem.2018.07.002_bib0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2018.07.002_bib0046","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0047","first-page":"5048","article-title":"Chimeric antigen receptor induced cytopenia differs from chemotherapy induced myelosuppression","volume":"130","author":"Shalabi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0048","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1084\/jem.20050137","article-title":"Differential contributions of central and effector memory T cells to recall responses","volume":"202","author":"Roberts","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0049","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T-cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0050","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.07.002_bib0051","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T-cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0052","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0053","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2018.07.002_bib0054","first-page":"1993","article-title":"Automated manufacture of CAR19 donor lymphocytes incorporated into an escalated dose DLI protocol: Preliminary results from the CARD study","volume":"130","author":"Roddie","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T-cell proliferation in patients with pediatric malignancies","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0056","doi-asserted-by":"crossref","first-page":"96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T-cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.exphem.2018.07.002_bib0057","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T-cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2018.07.002_bib0058","doi-asserted-by":"crossref","first-page":"14063","DOI":"10.1038\/mtm.2014.63","article-title":"Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy","volume":"2","author":"Wielgosz","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.exphem.2018.07.002_bib0059","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1038\/srep09021","article-title":"Construction of stable packaging cell lines for clinical lentiviral vector production","volume":"5","author":"Sanber","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2018.07.002_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.07.002_bib0061","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2018.07.002_bib0062","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood.V128.22.281.281","article-title":"CARS in leukemia: Relapse with antigen-negative leukemia originating from a single B-cell expressing the leukemia-targeting CAR","volume":"128","author":"Lacey","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0063","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2018.07.002_bib0064","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.07.002_bib0065","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0066","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2018.07.002_bib0067","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0068","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2018.07.002_bib0069","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0070","first-page":"1319","article-title":"Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-naive and CAR-exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"130","author":"Maude","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0071","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood.V130.Suppl_1.809.809","article-title":"CD4\/CD8 T-cell selection enhances CD22 CAR-T-cell transduction and in vivo CAR-T expansion: Updated results on phase I anti-CD22 CAR dose expansion cohort","volume":"130","author":"Shah","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0072","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0073","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2018.07.002_bib0074","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2018.07.002_bib0075","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T-cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.07.002_bib0076","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2018.07.002_bib0077","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18306349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18306349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T12:53:09Z","timestamp":1717246389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X18306349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":77,"alternative-id":["S0301472X18306349"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.07.002","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}